Treatment of Uterine Sarcoma in Uterine Leiomyosarcoma

Clinical Scenario

This protocol addresses systemic treatment of uterine sarcoma in patients with uterine leiomyosarcoma (uLMS) — the principal histological subgroup within uterine sarcomas. The approach is specific to this clinical context.

Uterine Leiomyosarcoma

Uterine leiomyosarcomas represent the main subgroup of uterine sarcomas, constituting a distinct entity with its own systemic treatment pathway. Identifying this subtype is essential before selecting a treatment strategy.

Treatment Approach — Partial Overview

The protocol covers second-line and subsequent systemic therapy for uterine leiomyosarcoma, with several agent options available — the choice among them depends on prior treatment history and previous response.

Full regimen details, agent sequencing, evidence grades, and individualised selection criteria are in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2024-005823

uLMS are the main subgroup of uterine sarcomas.

For second-line therapy and more, available regimens include: the same regimen as above if not used as first-line therapy or if associated with previous response; trabectedin (I, B); gemcitabine±dacarbazine (II, B); pazopanib (I, B); dacarbazine (I, B).

View source ↗